Compliance Actions by Drug Class

Since the Compliance Policy Guide was published, FDA has removed numerous unapproved drug products from the market. Generally, the Agency has focused its enforcement efforts on classes of unapproved drugs or firms marketing unapproved drugs.


Balanced Salt Solution (ophthalmic) Drug Products


Carbinoxamine Drug Products


Codeine Sulfate, Codeine Phosphate or Dihydrocodeine Bitartrate Oral and Injectable Drug Products

Codeine Sulfate Tablets


Colchicine Products

Single-ingredient Oral Colchicine Products

Injectable Colchicine Products

Cough, Cold, and Allergy Products 

Epinephrine 0.3 mg prefilled single dose syringe


Ergotamine-Containing Drug Products


Timed-Release Drug Products Containing Guaifenesin


Hydrocodone Drug Products

Unapproved Narcotics Containing Morphine Sulfate, Hydromorphone, or Oxycodone

Unapproved Nitroglycerin Sublingual Tablets

Unapproved Ophthalmic Drug Products

     Fluorescein Injection

     Freshkote Sterile Ophthalmic Solution

    Pilocarpine Hydrochloride Ophthalmic Solutions

Unapproved Otic Drug Products

  • Unapproved and Misbranded Otic Prescription Drug Products

Unapproved Oxycodone Single-Ingredient, Immediate Release Drug Products for Oral Administration

Topical Drug Products Containing Papain

Quinine Sulfate Drug Products

Sodium Nitrite Injection and Sodium Thiosulfate Injection Products

Trimethobenzamide Hydrochloride Suppositories

  • FDA News: FDA Announces that Companies Must Stop Marketing Suppository Products Containing Trimethobenzamide (Issued April 6, 2007)
  • Federal Register Notice [HTML] [PDF] (April 9, 2007)


Page Last Updated: 07/17/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.